Conformation
Analysis and Self-Consistent Field Energy of Immune Response Modifier,
1-(2-methylpropyl)-1H-imidazo[4,5]quinolin-4-amine (Imiquimod)
I.E.
Otuokere* and F.J. Amaku
Department
of Chemistry, Michael Okpara University of
Agriculture, Umudike, Nigeria
*Corresponding Author E-mail: ifeanyiotuokere@gmail.com
ABSTRACT:
1-(2-methylpropyl)-1H-imidazo[4,5]quinolin-4-amine
(imiquimod) is an immune response modifier and is
used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. Conformational analysis and geometry
optimization of imiquimiod was performed according to
the Hartree-Fock (HF) calculation method by ArgusLab 4.0.1 software.
Molecular mechanics calculations were based on specific interactions
within the molecule. These interactions included stretching or compressing of
bond beyond their equilibrium lengths and angles, torsional
effects of twisting about single bonds, the Van der
Waals attractions or repulsions of atoms that came close together, and the
electrostatic interactions between partial charges in imiquimod
due to polar bonds. The steric energy for imiquimiod was
calculated to be 59.09 kcal/mol. It was concluded that
the lowest energy and most stable conformation of imiquimiod
was 59.09 kcal/mol.
The most energetically favourable conformation
of imiquimiod
was found to have a heat of formation of 908.38
kcal/mol. The self-consistent field (SCF) energy was calculated by
geometry convergence function using ArgusLab
software. The most feasible position for the drug to interact with the receptor
was found to be -95.99 au (-60240.26
kcal/mol).
KEYWORDS: Imiquimod, self-consistent field, Arguslab software, conformational analysis.
INTRODUCTION:
Imiquimod acts on several
levels, which appear to synergistically underlie the profound antitumoral activity of the compound [1]. Imiquimod is
a prescription medication that acts as an immune response modifier and is used
to treat genital warts, superficial basal cell carcinoma, and actinic keratosis [2]. It is known that
imiquimod signals to the innate arm of the immune
system through the toll-like receptor 7 (TLR7), commonly involved in
pathogen recognition [3]. Cells activated by imiquimod
via TLR-7 secrete cytokines and tumor necrosis factor [4].
There is evidence that imiquimod, when applied to skin, can lead to the activation of Langerhans cells
, which subsequently migrate to local lymph nodes to activate the adaptive immune system [5]. Other cell types activated by imiquimod include natural killer cells, macrophages and B-lymphocytes [6]. A molecule is considered as a collection of atoms held together by classical forces. These forces are described by potential energy function of structural features like bond lengths, bond angles and torsion angles etc. The energy (E) of the molecule is calculated as a sum of terms as in equation (1).E = Estretching + Ebending
+ Etorsion + EVander
Waals + Eelectrostatic + Ehydrogen bond + cross term (equation
1). These terms are of importance for
the accurate calculation of geometric properties of molecules. The set of
energy functions and the corresponding parameters are called a force field and
can be generated using Argus Lab [7]. Argus Lab is the electronic
structure program that is based on the quantum mechanics, it predicts the potential
energies, molecular structures; geometry optimization of structure, vibration
frequencies of coordinates of atoms, bond length and bond angle [8].
Local charges such as Mulliken charges and ZDO
charges are also generated from arguslab using the
AM1 parameterized method. In the zero deferential overlap (ZDO) approximation,
the product of two deferent atomic orbitals is set to
zero. The integra which survives the ZDO
approximation was partly computed using the uniform charge sphere and the rest
parameterized. The result produced is the integrated form of Hückel Theory which takes into account electron repulsion. Mulliken charges arise from
the Mulliken population analysis [9.10] and
provide a means of estimating partial atomic charges from
calculations carried out by the methods of computational chemistry, particularly
those based on the linear combination of atomic orbitals molecular
orbital method, and are routinely used as variables in linear
regression (QSAR) procedures [11, 12].
MATERIALS AND METHODS:
The
structure of imiquimiod was drawn and constructed
using window based program of ACDLab Chem Sketch [13] and ArgusLab
4.0.1[14] softwares. Conformational analysis
(geometry optimization) of imiquimod was carried out using PM3
semi-empirical QM parameterization[15]
according to Hartree-Fock calculation method by
ArgusLab 4.0.1 software. Geometry of the molecule was
converged after the molecule is drawn and cleaned in ArgusLab
and the program then computes the energy until the maximum cycles reached for
the convergence (stopping point) of the molecule. Grid data was produced to
generate surfaces which is a cubic grid of points around the molecule where
various properties can be calculated such as electron densities, electrostatic
potentials (for both ground state and excited states) and any of the orbital[16]. ArgusLab subsequently uses these grid files to display
surfaces for the relevant properties. Many of these kinds of surfaces are shown
and described in this work. The electronic excited-state calculations were
carried out by ZINDO semi-empirical method [17,18]
which is parameterized for low energy excited-states of organic and organo-metallic molecules.
RESULTS AND
DISCUSSION:
Geometry
optimization was performed with the semi-empirical RHF/ Austin Model 1(AM1) parameterization[19]. Figure 1 shows the prospective
view of imiquimod and it property as generated by
ACD/ChemSketch. Figure 2 and 3 shows prospective view of active
conformation of imiquimod by Arguslab
software and the electron density clouds of imiquimod
by ACD Labs 3D viewer respectively. Figure 4 and 5 shows the highest occupied molecular orbital’s of imiquimod and the
Lowest unoccupied molecular orbital’s of imiquimod. Figure 6 shows the complete
surface of imiquimod with the color map. The SCF
energy cycle map is shown in Figure 7. Atomic coordinate of molecule is given
in Table1, bond length and bond angles are given in Tables 2 and 3 respectively,
which were calculated after geometry optimization of molecule from ArgusLab by using molecular mechanics calculation. Tables 4 and 5 shows the dihedral angles and ZDO charges of imiquimod respectively. Table 6 and 7 shows
calculated energy of imiquimiod molecule and the
Ground State Dipole (debye).
ArgusLab
was used to see what happened to the electrons in imiquimod
when it absorbed light. Surfaces were made to explore this fascinating
phenomenon. Imiquimod absorbsed
energy in the form of UV/visible light, it made a transition from the ground
electronic state to an excited electronic state. The excited and ground
states have different distributions of electron density. This property is
often valuable and sought after by chemists who are interested in molecules
that are useful as dyes, sunscreens, etc[14]. The HOMO is localized to the plane of the
molecule and is a non-bonding molecular orbital. The LUMO is
perpendicular to the plane of the molecule and is a combination of the pz atomic orbitals.
The n->π* transition is dominated by the
excitation from the HOMO to the LUMO. The positive and negative phases of the
orbital are represented by the two colors, the red regions represent an
increase in electron density and the blue regions a decrease in electron
density. However, these calculations were examined in the ground state and also
in vacuum [14]. The electrostatic potential is a physical property
of a molecule that relates to how a molecule is first “seen” or “felt” by a
positive "test" charge at a particular point in space. A distribution
of electric charge creates an electric potential in the surrounding space. A
positive electric potential means that a positive charge will be repelled in
that region of space. A negative electric potential means that a positive
charge will be attracted. A portion of a molecule that has a negative
electrostatic potential will be susceptible to electrophilic
attack – the more negative the better [14]. QuickPlot
ESP mapped density generates an electrostatic potential map on the total
electron density contour of the molecule. The electron density surface depicts
locations around the molecule where the electron probability density is equal [14].
This gives an idea of the size of the molecule and its susceptibility to electrophilic attack.
Electron density surface of imiquimod
using PM3 geometry which shows the complete surface with the color map.
The surface color reflects the magnitude and polarity of the electrostatic
potential. The color map shows the ESP energy (in hartrees)
for the various colors. The red end of the spectrum shows regions of highest
stability for a positive test charge, magenta/ blue show the regions of least
stability for a positive test charge [14].These images show that the
triple and double bonded end of the molecule is electron rich relative to the
single bonded end [14].
The self-consistent
field (SCF) energy is the average interaction between a given particle and
other particles of a quantum-mechanical system consisting of many particles. Beacause the problem of many interacting particles is very
complex and has no exact solution; calculations are done by approximate
methods. One of the most often used approximated methods of quantum mechanics
is based on the interaction of a self-consistent field, which permits the
many-particle problem to be reduced to the problem of a single particle moving
in the average self-consistent field produced by the other particles [20].
The final SCF energy of imiquimod was found to be
-95.99 au (-60240.26 kcal/mol)
It should be noted
that the Mulliken charges do not reproduce the electostatic potentials of a molecule very well. Mulliken charges were calculed by
determining the electron population of each atom as defined by the basis functions [21].
The standard heat of formation of a compound is the enthalpy change for
the formation of 1 mole of the compound from its constituent elements in their
standard states at 1 atmosphere. Its symbol is ΔHfθ. The most energetically favourable
conformation of imiquimod was found to have a heat of
formation of 908.38 kcal/mol
via use of the Argus Lab software [14]. The steric energy calculated for imiquimod
was found to be 0.09 a.u. (59.09
kcal/mol).
Figure 1: Prospective view of 1-(2-methylpropyl)-1H-imidazo[4,5]quinolin-4-amine
(imiquimod)
Table 1:
Atomic coordinates of Imiqimiod.
|
S.No |
Atoms |
X |
Y |
Z |
|
1 |
C |
20.412800 |
12.843300 |
0.000000 |
|
2 |
N |
20.412800 |
14.173300 |
0.000000 |
|
3 |
C |
19.260900 |
12.178300 |
0.000000 |
|
4 |
C |
19.260900 |
14.838300 |
0.000000 |
|
5 |
C |
18.109100 |
12.843300 |
0.000000 |
|
6 |
C |
18.109100 |
14.173300 |
0.000000 |
|
7 |
N |
16.844200 |
12.432400 |
0.000000 |
|
8 |
C |
16.062500 |
13.508300 |
0.000000 |
|
9 |
N |
16.844100 |
14.584300 |
0.000000 |
|
10 |
C |
21.564700 |
10.848300 |
0.000000 |
|
11 |
C |
21.564700 |
12.178300 |
0.000000 |
|
12 |
C |
20.412800 |
10.183300 |
0.000000 |
|
13 |
C |
19.261000 |
10.848300 |
0.000000 |
|
14 |
N |
19.260900 |
16.168300 |
0.000000 |
|
15 |
C |
16.433200 |
11.167500 |
0.000000 |
|
16 |
C |
15.132300 |
10.890900 |
0.000000 |
|
17 |
C |
14.721300 |
9.626000 |
0.000000 |
|
18 |
C |
14.242400 |
11.879300 |
0.000000 |
|
19 |
H |
18.109000 |
16.833300 |
0.000000 |
|
20 |
H |
20.412700 |
16.833400 |
0.000000 |
Table 2: Bond length of imiquimod.
|
Atoms |
Bond length |
|
(C1)-(C3) |
1.458000 |
|
(C1)-(N2) |
1.433804 |
|
(C1)-(C11) |
1.323387 |
|
(N2)-(C4) |
1.301961 |
|
(C3)-(C5) |
1.458000 |
|
(C3)-(C13) |
1.323387 |
|
(C4)-(C6) |
1.458000 |
|
(C4)-(N14) |
1.343384 |
|
(C5)-(C6) |
1.323387 |
|
(C5)-(N7) |
1.433804 |
|
(C6)-(N9) |
1.433804 |
|
(N7)-(C8) |
1.433804 |
|
(N7)-(C15) |
1.436817 |
|
(C8)-(N9) |
1.301961 |
|
(C10)-(C11) |
1.458000 |
|
(C10)-(C12) |
1.323387 |
|
(C12)-(C13) |
1.458000
|
|
(N14)-(H19) |
1.048529 |
|
(N14)-(H20) |
1.048529 |
|
(C15)-(C16) |
1.464000 |
|
(C16)-(C17) |
1.464000 |
|
(C16)-(C18) |
1.464000 |
Table 3: Bond angles of imiquimod.
|
Atoms |
Bond angles |
Alternate angles |
|
(C3)-(C1)-(N2) |
120.000000 |
257.053574 |
|
(C3)-(C1)-(C11) |
120.000000 |
216.488007 |
|
(C5)-(C3)-(C1) |
120.000000 |
188.442082 |
|
(C1)-(C3)-(C13) |
120.000000 |
216.488007 |
|
(N2)-(C1)-(C11) |
120.000000 |
295.980973 |
|
(C1)-(N2)-(C4) |
120.000000 |
227.506158 |
|
(C1)-(C11)-(C10) |
120.000000 |
216.488007 |
|
(N2)-(C4)-(C6) |
120.000000 |
294.480480 |
|
(N2)-(C4)-(N14) |
120.000000 |
446.697620 |
|
(C5)-(C3)-(C13) |
120.000000 |
216.488007 |
|
(C3)-(C5)-(C6) |
120.000000 |
216.488007 |
|
(C3)-(C5)-(N7) |
120.000000 |
257.053574 |
|
(C3)-(C13)-(C12) |
120.000000 |
216.488007 |
|
(C6)-(C4)-(N14) |
120.000000 |
282.167276 |
|
(C4)-(C6)-(C5) |
120.000000 |
216.488007 |
|
(C4)-(C6)-(N9) |
120.000000 |
257.053574 |
|
(C4)-(N14)-(H19) |
120.000000 |
124.657989 |
|
(C4)-(N14)-(H20) |
120.000000 |
124.657989 |
|
(C6)-(C5)-(N7) |
120.000000 |
295.980973 |
|
(C5)-(C6)-(N9) |
120.000000 |
295.980973 |
|
(C5)-(N7)-(C8) |
120.000000 |
198.144139 |
|
(C5)-(N7)-(C15) |
120.000000 |
197.520556 |
|
(C6)-(N9)-(C8) |
120.000000 |
227.506158 |
|
(C8)-(N7)-(C15) |
120.000000 |
197.520556 |
|
(N7)-(C8)-(N9) |
120.000000 |
402.764879 |
|
(N7)-(C15)-(C16) |
120.000000 |
254.659028 |
|
(C11)-(C10)-(C12)
|
120.000000 |
216.488007 |
|
(C10)-(C12)-(C13) |
120.000000 |
216.488007 |
|
(H19)-(N14)-(H20) |
120.000000 |
70.257681 |
|
(C15)-(C16)-(C17) |
120.000000 |
186.134654 |
|
(C15)-(C16)-(C18) |
120.000000 |
186.134654 |
|
(C17)-(C16)-(C18) |
120.000000 |
186.134654 |
Table 4:
Dihedral angles of imiquimod.
|
Atoms |
Dihedral angles |
|
(C5)-(C3)-(C1)-(N2) |
2.500000 |
|
(C13)-(C3)-(C1)-(N2) |
2.500000 |
|
(C3)-(C1)-(N2)-(C4) |
5.000000 |
|
(C5)-(C3)-(C1)-(C11) |
2.500000 |
|
(C13)-(C3)-(C1)-(C11) |
2.500000 |
|
(C3)-(C1)-(C11)-(C10) |
19.486776 |
|
(C1)-(C3)-(C5)-(C6) |
2.500000 |
|
(C1)-(C3)-(C5)-(N7) |
2.500000 |
|
(C1)-(C3)-(C13)-(C12) |
19.486776 |
|
(C4)-(N2)-(C1)-(C11) |
5.000000 |
Table 4:
continued
|
Atoms |
Dihedral angles |
|
(N2)-(C1)-(C11)-(C10) |
19.486776 |
|
(C1)-(N2)-(C4)-(C6) |
19.486776 |
|
(C1)-(N2)-(C4)-(N14) |
19.486776 |
|
(C1)-(C11)-(C10)-(C12) |
10.000000 |
|
(N2)-(C4)-(C6)-(C5) |
2.500000 |
|
(N2)-(C4)-(C5)-(N9) |
2.500000 |
|
(N2)-(C4)-(N14)-(H19) |
6.737110 |
|
(N2)-(C4)-(N14)-(H20) |
6.737110 |
|
(C6)-(C5)-(C3)-(C13) |
2.500000 |
|
(N7)-(C5)-(C3)-(C13) |
2.500000 |
|
(C5)-(C3)-(C13)-(C12) |
19.486776 |
|
(C3)-(C5)-(C6)-(C4) |
9.743388 |
|
(C3)-(C5)-(C6)-(N9) |
9.743388 |
|
(C3)-(C5)-(N7)-(C8) |
2.500000 |
|
(C3)-(C5)-(N7)-(C15) |
2.500000 |
|
(C3)-(C13)-(C12)-(C10) |
10.000000 |
|
(C5)-(C6)-(C4)-(N14) |
2.500000 |
|
(N9)-(C6)-(C4)-(N14) |
2.500000 |
|
(C6)-(C4)-(N14)-(H19) |
6.737110 |
|
(C6)-(C4)-(N14)-(H20) |
6.737110 |
|
(C4)-(C6)-(C5)-(N7) |
9.743388 |
|
(C4)-(C6)-(N9)-(C8) |
5.000000 |
|
(N9)-(C6)-(C5)-(N7) |
9.743388 |
|
(C6)-(C5)-(N7)-(C8) |
12.500000 |
|
(C6)-(C5)-(N7)-(C15) |
2.500000 |
|
(C5)-(C6)-(N7)-(C8) |
5.000000 |
|
(C5)-(N7)-(C8)-(N9) |
5.000000 |
|
(C5)-(N7)-(C15)-(C16) |
5.000000 |
|
(C6)-(N9)-(C8)-(N7) |
38.973552 |
|
(N9)-(C8)-(N7)-(C15) |
5.000000 |
|
(C8)-(N7)-(C15)-(C16) |
5.000000 |
|
(N7)-(C15)-(C16)-(C17) |
5.000000 |
|
(N7)-(C15)-(C16)-(C18) |
5.000000 |
|
(C11)-(C10)-(C12)(C13) |
38.973552 |
Table 5:
List of Mulliken Atomic Charges and ZDO Atomic
Charges of Imiquimod
|
S.NO |
Atoms |
ZDO atomic charges |
Mulliken
atomic charges |
|
1 |
C |
1.6232 |
1.8586 |
|
2 |
N |
4.99742 |
5.0036 |
|
3 |
C |
-1.6737 |
-1.8782 |
|
4 |
C |
3.9999 |
4.0007 |
|
5 |
C |
3.8561 |
4.0412 |
|
6 |
C |
3.99941 |
4.0046 |
|
7 |
N |
-0.5890 |
-0.7363 |
|
8 |
C |
3.7314 |
3.8186 |
|
9 |
N |
4.9995 |
4.9999 |
|
10 |
C |
-4.0000 |
-4.0021 |
|
11 |
C |
-3.9476 |
-4.0718 |
|
12 |
C |
-4.0000 |
-4.0005 |
|
13 |
C |
-3.9978 |
-4.0212 |
|
14 |
N |
5.0000 |
5.0000 |
|
15 |
C |
-3.9991 |
-4.0154 |
|
16 |
C |
-4.0000 |
-4.0003 |
|
17 |
C |
-4.0000 |
-4.0000 |
|
18 |
C |
-3.9999 |
-4.0015 |
|
19 |
H |
1.0000 |
1.0000 |
|
20 |
H |
1.0000 |
1.0000 |
Table 6:
Final energy evaluation
|
S.No. |
Force field |
Energy components (au) |
|
1 |
MM bond (Estr) |
0.00328545 |
|
2 |
MM (Ebend)+ (Estr‑bend) |
0.06455953 |
|
3 |
MM dihedral (Etor) |
0.00000000 |
|
4 |
MM ImpTor (Eoop) |
0.00000000 |
|
5 |
MM vdW (EVdW) |
0.02633195 |
|
6 |
MM coulomb (Eqq) |
0.00000000 |
|
Total |
0.09417693a.u.(59.09697057kcal/mol) |
|
MM = Molecular mechanics
Table 7 :
Ground State Dipole (debye)
|
X |
Y |
Z |
Length |
|
106.34604271 |
-614.51953993 |
-0.00000000 |
623.65354626 |
CONCLUSIONS:
This work showed that the calculated steric energy for imiquimod was 59.09697057 kcal/mol. It was concluded that the lowest
energy and most stable conformation of imiquimod was 59.09697057 kcal/mol.
The most energetically favourable conformation
of imiquimiod was found to have a heat of formation
of 908.38 kcal/mol. The self-consistent field
(SCF) energy was calculated by geometry convergence function using ArgusLab software. The most feasible position for the drug
to interact with the receptor was found to be -95.99 au (-60240.26 kcal/mol). At this point imiquimiod will be more active as a chemotherapy agent.
REFERENCES:
1.
Randall LH. TLR-7 Agonists for the
Treatment of Viral Hepatitis. In
Successful Strategies for the Discovery of Antiviral Drugs. Eds Manoj CD and Nicholas AM. RSC drug discovery series, Royal Society of Chemistry, 2013.
2.
Miller RL, Gerster
JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied
topically: a novel immune response modifier and a new class of drug. Int J Immunopharmacol 21 (1) ; 1999 : 1–14.
3.
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds
activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat
Immunol. 3(2): 2002 :
196–200.
4.
Bilu D, Sauder DN. Imiquimod: modes of action. Br. J. Dermatol.
149 Suppl 66; 2003: 5 – 8.
5.
Van SM, Van
BM, Ten KFJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger
MP, Helmerhorst TJ. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. The New England Journal of
Medicine, 358 (14);
2008: 1465 – 1473.
6.
Buck HW, Guth
KJ. Treatment of vaginal intraepithelial neoplasia
(primarily low grade) with imiquimod 5%
cream". Journal of lower genital
tract disease, 7(4); 2003: 290
–293.
7.
Cramer CJ and Truhlar DG. AM1-SM2
and PM3-SM3 parameterized SCF solvation models for
free energies in aqueous solution. Computer-Aided
Mol. Design, 6; 1992 : 629-666.
8.
Peng C, Ayali PY, Schlegel HB and Frisch MJ. Using redundant
internal coordinates to optimize equilibrium geometries and transition states. J.Comp.Chem., 16; 1995 :
49-51.
9.
Mulliken RS. Electronic Population Analysis on LCAO-MO Molecular Wave Functions.
I. The Journal of Chemical
Physics 23(10);
1955: 1833–1840.
10. Csizmadia LG Theory and
Practice of MO Calculations on Organic Molecules, Elsevier, Amsterdam, 1976.
11. Leach AR. Molecular modelling: principles and applications. Englewood
Cliffs, N.J: Prentice Hall. 2001
12. Ohlinger WS, Philip EK,
Bernard JD, Warren JH. Efficient
Calculation of Heats of Formation. The
Journal of Physical Chemistry A (ACS Publications), 113(10); 2009: 2165–2175.
13.
http://www.acdlab.com
14.
Mark AT, ArgusLab 4.0, Planaria Software LLC, Seattle, WA. 2003. http://www.arguslab.com
15.
Stewart JJP. Optimization of parameters for semiempirical methods I-Method. J. Comp. Chem., 10;
1989:209-220.
16.
Karelson MM and Zerner MC. Theoretical treatment of solvent effects on
electronic spectroscopy. J. Phys. Chem., 96; 1992: 6469-6957.
17. Ridley J and Zerner M. Zindo Semi-empirical
Hamiltonian method. Tempel of Central Airport, Berl. 32; 1973:
111-134.
18.
Zerner MC. Semiempirical
molecular orbital methods. In: Libkowitz, KB
and Boyd, DB editors. Reviews in Computational Chemistry, 2nd ed., VCS
Publishers Inc., 1991,
pp. 313-366.
19.
Dewar MJS, Zoobisch EG, Healy EF
and Stewart JJP. AM1: A new general purpose quantum mechanical molecular model.
J. Am. Chem. Soc. 107; 1985: 3902 - 3910.
20.
http://www.thefreedictionary.com
21.
http://www.ambermd.org
Received on 08.08.2015 Accepted on 24.08.2015
© Asian Pharma
Press All Right Reserved
Asian J. Res. Pharm.
Sci. 5(3): July-Sept.; Page
175-180
DOI: 10.5958/2231-5659.2015.00026.0